SAN LUIS OBISPO, California – May 10, 2004 – FzioMed, Inc. today announced that it will present at the Rodman & Renshaw Techvest Global Healthcare Conference to be held May 12-14, 2004, at Claridge’s Hotel in London, UK. Ronald F. Haynes, President and CEO of FzioMed, is scheduled to speak at 2:30 pm BST on Thursday May 13 in the Mirror Room at Claridge’s Hotel.
Mr. Haynes will provide an update on FzioMed’s biomaterial product pipeline and recent accomplishments, including clinical results from the company’s adhesion prevention studies in gynecology and the successful EU launch of its Oxiplex/SP Adhesion Barrier Gel for spine surgery.
FzioMed is a privately held medical company engaged in the development and commercialization of synthetic, absorbable biomaterials based on the company’s patented Oxiplex technology. FzioMed is developing products for the prevention of post-surgical adhesions, for tissue healing and augmentation, as injectables, and for the delivery of drugs. Oxiplex is an innovative polymer technology with potential uses across a wide variety of specialties including orthopedics, gynecology, general surgery, cardiac, neurosurgery and aesthetic surgery. FzioMed products include Oxiplex/SP, the leading adhesion barrier for spine surgery. Other FzioMed products are in various stages of clinical and pre-clinical development, and commercialization, and are directed towards high growth markets in the rapidly growing field of biosurgery materials.
FzioMed® and Oxiplex® are registered trademarks of FzioMed, Inc.